G1 Therapeutics Inc
NASDAQ:GTHX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
G1 Therapeutics Inc
Net Income (Common)
G1 Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G1 Therapeutics Inc
NASDAQ:GTHX
|
Net Income (Common)
-$44.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$8.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
23%
|
|
G1 Therapeutics Inc
Glance View
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.
See Also
What is G1 Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-44.8m
USD
Based on the financial report for Jun 30, 2024, G1 Therapeutics Inc's Net Income (Common) amounts to -44.8m USD.
What is G1 Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
15%
Over the last year, the Net Income (Common) growth was 42%. The average annual Net Income (Common) growth rates for G1 Therapeutics Inc have been 24% over the past three years , 15% over the past five years .